Prolonging time to progression and survival in relapsed/refractory multiple myeloma
Pieter Sonneveld
Department of Haematology Erasmus Medical Center Erasmus University
P.O. Box 20403000 CA Rotterdam, The Netherlands
Each year, over 16,500 new cases of multiple myeloma (MM) are diagnosed in the USA alone, making it the second most common type of haematological malignancy after non-Hodgkin’s lymphoma.1 Current treatment options for MM are non-curative, and the 5-year survival rate for all patients with MM has improved only slightly over the last 20−25 years, from 25% to 32%.
[>Read full article in PDF]